Please provide your email address to receive an email when new articles are posted on . Adbry is now available in the U.S. as a 300 mg/2 mL single-dose autoinjector for adults with atopic dermatitis.

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc. announced today the availability of the Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently ...

Please provide your email address to receive an email when new articles are posted on . Adbry is approved for moderate to severe atopic dermatitis. The autoinjector delivers a single 300 mg/mL dose.

The new autoinjector will provide another option for adult patients in addition to the pre-filled syringe administration that is currently available. Prior to the introduction of the autoinjector, ...

The Adbry autoinjector is for use in adults only. A new single-dose autoinjector presentation of Adbry ® (tralokinumab-ldrm) is now available for use in the treatment of moderate to severe atopic ...